A non-faradaic label-free cortisol biosensor was demonstrated using MoS2 nanosheets integrated into a nanoporous flexible electrode system. Low volume (1–5 μL) sensing was achieved through use of a novel sensor stack design comprised of vertically aligned metal electrodes confining semi-conductive MoS2 nanosheets. The MoS2 nanosheets were surface functionalized with cortisol antibodies towards developing an affinity biosensor specific to the physiological relevant range of cortisol (8.16 to 141.7 ng/mL) in perspired human sweat. Sensing was achieved by measuring impedance changes associated with cortisol binding along the MoS2 nanosheet interface using electrochemical impedance spectroscopy. The sensor demonstrated a dynamic range from 1–500 ng/mL with a limit of detection of 1 ng/mL. A specificity study was conducted using a metabolite expressed in human sweat, Ethyl Glucuronide. Continuous dosing studies were performed during which the sensor was able to discriminate between four cortisol concentration ranges (0.5, 5, 50, 500 ng/mL) for a 3+ hour duration. Translatability of the sensor was shown with a portable form factor device, demonstrating a comparable dynamic range and limit of detection for the sensor. The device demonstrated a R2 correlation value of 0.998 when comparing measurements to the reported impedance values of the benchtop instrumentation.

Brighter Bites is a school-based health promotion program that delivers fresh produce and nutrition education to low-income children and their families across six cities in the U.S. This paper provides a perspective on how, despite COVID-19-related school closures, Brighter Bites pivoted rapidly to collaborate with medical and public health institutions to improve health and food literacy among their families. Through these partnerships, Brighter Bites was able to rapidly provide accurate, evidence-based information related to COVID-19 and other social needs, including food, housing, transportation, and access to healthcare, to help fill a needed gap in vulnerable communities.

No abstract

No abstract

Case: One week after receiving a COVID-19 vaccine in his left deltoid, a 34-year-old man developed severe right periscapular pain that lasted 2 weeks and was followed by profound right shoulder girdle atrophy and weakness. Both the pain and motor deficits resolved over the subsequent 4 months. Conclusion: Parsonage-Turner syndrome (PTS) is an idiopathic brachial plexopathy that can develop in the setting of recent vaccination and lead to significant shoulder pain and weakness. Given the worldwide increase in newly vaccinated patients, orthopaedic surgeons should take detailed histories to identify potential triggers (recent vaccination or illness) that point toward PTS rather than musculoskeletal pathology.